(NASDAQ: CGEM) Cullinan Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.98%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.98%.
Cullinan Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast CGEM's revenue for 2025 to be $885,220,005, with the lowest CGEM revenue forecast at $885,220,005, and the highest CGEM revenue forecast at $885,220,005. On average, 2 Wall Street analysts forecast CGEM's revenue for 2026 to be $1,601,540,033, with the lowest CGEM revenue forecast at $607,851,070, and the highest CGEM revenue forecast at $2,595,228,996.
In 2027, CGEM is forecast to generate $2,228,098,753 in revenue, with the lowest revenue forecast at $444,970,589 and the highest revenue forecast at $3,554,276,349.